Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, China.
Tsinghua Clinical Research Institute (TCRI), School of Medicine, Tsinghua University, Beijing, China.
Front Immunol. 2022 Jul 4;13:919979. doi: 10.3389/fimmu.2022.919979. eCollection 2022.
As the coronavirus disease 2019 (COVID-19) pandemic continues worldwide, vaccination has been considered an effective measure to protect people from the COVID-19 and end the pandemic. However, for patients with rheumatic diseases (RD), concern for the induction of RD flare may combat the enthusiasm for vaccination. In general, current evidence doesn't support the increased risk of disease flare after COVID-19 vaccination. However, the disease flare of RDs may be triggered by COVID-19 vaccinations, especially for patients with high disease activity. Most of these flares after vaccination are mild and need no treatment escalation. Considering the benefits and risks, RD patients are recommended to receive the COVID-19 vaccination but should be vaccinated when the RDs are in stable states.
随着 2019 年冠状病毒病（COVID-19）大流行在全球范围内持续，接种疫苗被认为是保护人们免受 COVID-19 和结束大流行的有效措施。然而，对于患有风湿性疾病（RD）的患者，担心引发 RD 发作可能会打击接种疫苗的热情。一般来说，目前的证据并不支持 COVID-19 疫苗接种后疾病发作风险增加。然而，COVID-19 疫苗接种可能会引发 RD 发作，特别是对于疾病活动度高的患者。这些疫苗接种后的大多数发作都比较轻微，不需要升级治疗。考虑到利弊，建议 RD 患者接种 COVID-19 疫苗，但应在 RD 处于稳定状态时接种疫苗。
